Zhengye Biotechnology Holding (ZYBT) Total Current Liabilities (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Total Current Liabilities for 3 consecutive years, with $17.0 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities fell 10.22% year-over-year to $17.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.0 million (down 10.22% YoY) and the FY2025 annual result came in at $17.2 million, down 7.46% from the prior year.
• Total Current Liabilities retreated to $17.0 million in Q4 2025 per ZYBT's latest filing, from $18.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ZYBT reached as high as $20.9 million in Q4 2023 and fell as low as $17.0 million in Q4 2025.
• A 3-year average of $18.9 million and a median of $18.9 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities declined 9.32% — and 2025, when it fell 10.22%.
• Year by year, Total Current Liabilities stood at $20.9 million in 2023, then dropped by 9.32% to $18.9 million in 2024, then declined by 10.22% to $17.0 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $17.0 million, $18.8 million, and $18.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.